title: Current status of HIV therapy: I. Antiretroviral agents.
abstract: The clinician's armamentarium is no longer limited to zidovudine as the only antiretroviral agent that enhances both quality and length of life. ddI has shown clinical benefit in patients previously treated with zidovudine. Recently, the combination of zidovudine and ddC has been approved on the basis of surrogate marker activity; its clinical role awaits results of ongoing trials.
authors.affiliation: Treatment Research Program, National Institute of Allergy and Infectious Diseases, Bethesda.
authors.forename: D F
authors.initials: DF
authors.lastname: Hoth
authors.forename: M W
authors.initials: MW
authors.lastname: Myers
authors.forename: D S
authors.initials: DS
authors.lastname: Stein
mesh_terms: D016915:AIDS Vaccines / Q000494:pharmacology / Q000627:therapeutic use; D000359:Aftercare; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002985:Clinical Protocols / Q000592:standards; D002986:Clinical Trials as Topic; D003663:Decision Trees; D015224:Dideoxynucleosides / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015497:HIV-1; D006801:Humans; D007372:Interferons / Q000494:pharmacology / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D016915:AIDS Vaccines; D000998:Antiviral Agents; D015224:Dideoxynucleosides; D007372:Interferons